Vor Biopharma Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Vor Biopharma Inc. operates as a clinical-stage biotechnology company primarily concentrating on the development of innovative therapies for severe autoimmune conditions. The firm's central asset is telitacicept, a novel dual-target fusion protein designed to inhibit critical cytokines, BlyS (BAFF) and APRIL, thereby reducing autoreactive B cells and autoantibody production associated with autoimmune diseases. Vor Biopharma holds exclusive global rights, outside of Greater China, to develop and commercialize this agent, which is already approved in China for generalized myasthenia gravis (gMG), systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA). This strategic shift, initiated in June 2025 with a change in leadership and a significant capital raise, repositions the company to advance telitacicept through its global clinical development. Previously, the company focused on engineered hematopoietic stem cell therapies for hematological cancers like acute myeloid leukemia (AML), a direction that has largely been wound down. Vor Biopharma, established in 2015, maintains its headquarters in Cambridge, Massachusetts, and funds its pipeline progression through ongoing public offerings and strategic investments.
Company News
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Vor Biopharma (NASDAQ:VOR) Shares Up 5.3% – What’s Next?
Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis
Vor Biopharma: A Funded Replication Story With Franchise Potential
Vor Biopharma Inc. (VOR) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Vor Completes Enrollment of Global Phase 3 UPSTREAM MG Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia Gravis
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Bank of America Corp DE Has $2.01 Million Stock Holdings in Vor Biopharma Inc. $VOR
Vor Bio To Participate in Upcoming September Conferences
Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Vor Bio Appoints David Zaccardelli to Board of Directors
Vor Biopharma: A Financed Autoimmune Pivot With More Substance Than The Market Realizes
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Telitacicept Receives NMPA Approval for the Treatment of Sjögren's Disease in China
Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Vor Bio to Participate in the 2026 Jefferies Global Healthcare Conference